Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

McKesson Europe AG CAKFY OTC

Other OTC • Healthcare • Medical - Distribution • DE • USD

SharesGrow Score
34/100
1/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

McKesson Europe AG (CAKFY) is a Medical - Distribution company in the Healthcare sector, currently trading at $4.10. It has a SharesGrow Score of 32/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Financials: revenue is $9.3B, -22%/yr average growth. Net income is $49M (loss), growing at -1833.2%/yr. Net profit margin is -0.5% (negative). Gross margin is 8.7% (-1 pp trend).

Balance sheet: total debt is $184M against $2.5B equity (Debt-to-Equity (D/E) ratio 0.07, conservative). Current ratio is 1.82 (strong liquidity). Debt-to-assets is 3.6%. Total assets: $5.1B.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 25/100 (Fail), Health 83/100 (Pass), Moat 35/100 (Fail), Future ?/100 (Fail), Income 10/100 (Fail).

CAKFY SharesGrow Score Overview

34/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 25/100
strong — trend
HEALTH 83/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 35/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — CAKFY

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
CAKFY: -22%/yr revenue is, -1833.2%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
✗
PAST Fail
25/100
CAKFY: 1 / 4 years profitable. weak. Score = 1 / 4 × 100. ≥ 80 = Pass.
View details →
✓
HEALTH Pass
83/100
Balance sheet CAKFY: Debt-to-Equity (D/E) ratio 0.07 (conservative), Current ratio is 1.82 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
35/100
CAKFY: Gross margin is 8.7% (-1 pp trend), $5B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 35/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
✗
INCOME Fail
10/100
CAKFY: Net profit margin is -0.5%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range4.02-4.81
Volume428
Avg Volume (30D)6
Market Cap$5.37B
Beta (1Y)0.13
Dividend Yield$0.1700
Share Statistics
EPS (TTM)-0.05
Shares Outstanding$1.02B
IPO Date2010-02-16
Employees26,329
CEOTilo Köster
Financial Highlights & Ratios
Revenue (TTM)$9.26B
Gross Profit$803.8M
EBITDA$218.7M
Net Income$-49.4M
Operating Income$58.9M
Total Cash$5.3M
Total Debt$183.9M
Net Debt$178.6M
Total Assets$5.1B
Price / Earnings (P/E)-84.4
Price / Sales (P/S)0.58
Analyst Forecast
Company Info
CountryDE
ExchangeOther OTC
CurrencyUSD
ISINUS58155Y1064

Price Chart

Track all markets on TradingView
CAKFY
McKesson Europe AG ↗  ·  Other OTC
Healthcare • Medical - Distribution
4.02 52WK RANGE 4.81

People Also View

LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
 RHHBF
RHHBF
Roche Holding AG
$418.50
+1.82%
 RHHBY
RHHBY
Roche Holding AG
$51.02
+0.65%
 AZN
AZN
AstraZeneca PLC
$204.38
+1.06%
 NVSEF
NVSEF
Novartis AG
$156.48
+0.00%
 MRK
MRK
Merck & Co., Inc.
$119.96
-0.16%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message